New Delhi, May 02, 2019: Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma…
New Delhi, April 25, 2019: Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist…
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials Cambridge, March…
New Delhi, March 14, 2019: Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue…
Tokyo, February 17, 2019: Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase…
New Delhi, Febraury 14, 2019: Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency…
Tokyo, August 04, 2018: Eisai Co., Ltd. announced today that it has entered into an agreement to grant exclusive development…
Tokyo, June 24, 2018: AbbVie GK, Eisai Co., Ltd. and Eisai’s subsidiary for gastrointestinal diseases EA Pharma Co., Ltd.announced that the…